Cargando…
Alzheimer-Erkrankung – welche Substanzen befinden sich derzeit in Phase-III-Studien?
BACKGROUND: The recent approval of aduhelm/aducanumab by the US Food and Drug Administration (FDA) in June 2021 raised hopes that further substances against Alzheimer’s disease might be approved in the near future. OBJECTIVE: The current status of phase III studies for Alzheimerʼs disease was evalua...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Medizin
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534798/ https://www.ncbi.nlm.nih.gov/pubmed/35288774 http://dx.doi.org/10.1007/s00115-022-01275-5 |